Mer­ck has opened a new man­u­fac­tur­ing plant in Durham, NC which will make HPV vac­cines, in­clud­ing its quadri­va­lent vac­cine Gar­dasil and nine-va­lent vac­cine Gar­dasil 9 … ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated to produce bulk substance for its megablockbuster HPV vaccine Gardasil.

Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug giant announced Tuesday. Merck has opened a $1 billion, 225,000-square ...

(Reuters) -Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, as the drugmaker seeks to boost its U.S. manufacturing in the face of President Donald Trump's ...

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment DURHAM, N.C., March 11, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States ...

March 11 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid ...

March 11 (Reuters) - A federal judge ruled in favor of Merck (MRK.N), opens new tab in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers ...

STORY HIGHLIGHTS Merck opens new vaccine facility in Durham. New facility will manufacture HPV vaccines Gardasil and Gardasil 9. Merck plans to invest $8 billion more in U.S. by 2028. A global ...

Stephen Krahling was a published cancer researcher when vaccine maker Merck brought him on board as a virologist in 1999. That’s when he says he found himself embroiled in an all-hands-on-deck ...